

Diagnostic problems and prognostic factors in prostate cancer

Ph.D. Thesis

Miklós Tarján, M.D.

Supervisor:

Prof. Gábor Cserni, M.D., Ph.D., D.Sc.

Department of Pathology, University of Szeged

Department of Pathology and Clinical Cytology,

Central Hospital, Falun, Sweden

Szeged

2013

This thesis is dedicated to

the memory of my father, vitéz dr. Tarján Jenő (1935-2013),

Who has dedicated his life to cure people...

...for inspiring my fascination in science.

List of full papers that served as the basis of the Ph.D. thesis:

- I. **Tarján M**, Tot T. Prediction of extracapsular extension of prostate cancer based on systematic core biopsies. *Scand J Urol Nephrol* 2006;40:459-64. **IF(2006): 1,089**
- II. **Tarján M**. Prognostic significance of focal neuroendocrine differentiation in prostate cancer: cases with autopsy-verified cause of death. *Indian J Urol* 2010;26:41-45.
- III. **Tarján M**, Lenngren A, Hellberg D, Tot T. Immunohistochemical verification of ductal differentiation in prostate cancer. *APMIS* 2012;120:510-18. **IF(2012): 2,068**
- IV. **Tarján M**, Chen H-H, Tot T, Wu W, Lenngren A, Dean PB, Tabár L. Improved differentiation between ductal and acinar prostate cancer using 3-dimensional histology and biomarkers. *Scand J Urol Nephrol* 2012;46:258-66. **IF(2012): 1,007**

Others publications:

1. **Tarján M**, Cserni G. Tüdőembólia a patológus szemével. A gyakoriság, szezonális megítélése és a klinikai felismerés elemzése. *Cardiologia Hungarica* 1999;18(2):61-65.
2. Cserni G, Vajda K, **Tarján M**, Bori R, Svébis M, Baltás B. Nodal staging of colorectal carcinomas from quantitative and qualitative aspects. Can lymphatic mapping help staging? *Pathol Oncol Res* 1999;5:291-296.
3. Cserni G, **Tarján M**. Proszтата szövet az ovarium dermoid cystájában. *Orv Hetil.* 2000;141:355-356.

4. Cserni G, **Tarján M**, Bori R. Distance of lymph nodes from the tumor, an important feature in colorectal cancer specimens. *Arch Pathol Lab Med* 2001;125:246-249. **IF(2001): 1,257**
5. **Tarján M**, Cserni G, Szabó Z. Malignant fibrous histiocytoma of the kidney. *Scan J Urol Nephrol* 2001;53:518-520. **IF(2001): 0,722**
6. **Tarján M**, Cserni G, Szabó Z. Malignus fibrosus histiocytoma a vesében. *Magyar Urológia* 2001;13:188-194.
7. Cserni G, Kovács RB, **Tarján M**, Sápi Z, Domján Z, Szabó Z. Sarcomatoid renal cell carcinoma with foci of chromophobe carcinoma. *Pathol Oncol Res* 2002;8:142-144.
8. Vajda K, Cserni G, Svébis M, Baltás B, Bori R, **Tarján M**, Kocsis L. Sentinel nyirokcsomó meghatározása vastagbélrákok esetén. *Magyar Sebészet* 2002;55:375-377.
9. **Tarján M**. Órszem nyirokcsomó-biopszia Magyarországon. A sebészi onkológia forradalmi újításának hazai eredményei. *Magy Onkol.* 2002;46:315-21
10. **Tarján M**, Sápi Z, Bentzik A, Cserni G. Egy ritka uterus malignoma: adenosarcoma endometrii. *Lege Artis Medicinae* 2004;14:598-600.
11. Cserni G, Burzykowski T, Vinh-Hung V, Kocsis L, Boross G, Sinkó M, **Tarján M**, Bori R, Rajtár M, Tekle E, Maráz R, Baltás B, Svébis M. Axillary sentinel node and tumour-related factors associated with non-sentinel node involvement in breast cancer. *Jpn J Clin Oncol* 2004;34:519-524. **IF(2004): 0,96**
12. **Tarján M**, Sarkissov G, Tot T. Unclassified sex cord/gonadal stromal testis tumor with predominance of spindle cells. *APMIS* 2006;114:465-469. **IF(2006): 1,875**

13. Sebők J, **Tarján M**. [Discrepancies between clinical and pathological diagnoses-methods and pitfalls.] *Orv Hetil* 2008;149:1125-1135.
14. **Tarján M**, Ottlecz I, Tot T. Primary adenocarcinoma of the seminal vesicle. *Indian J Urol* 2009;25:143-145.
15. Tot T, Pekár G, Hofmeyer S, Sollie T, Gere M, **Tarján M**. The distribution of lesions in 1-14-mm invasive breast carcinomas and its relation to metastatic potential. *Virchows Arch* 2009;455:109-115. **IF(2009): 2,305**
16. Tot T, Pekár G, Hofmeyer S, Gere M, **Tarján M**, Hellberg D, Lindquist D. Molecular phenotypes of unifocal, multifocal, and diffuse invasive breast carcinomas. *Pathol Res Int* 2011; 2011:480960.
17. Tot T, Gere M, Pekár G, **Tarján M**, Hofmeyer S, Hellberg D, Lindquist D, Chen TH, Yen AM, Chiu SY, Tabár L. Breast cancer multifocality, disease extent, and survival. *Hum Pathol* 2011;42:1761-1769. **IF(2011): 2,876**
18. Lindquist D, Ahrlund-Richter A, **Tarján M**, Tot T, Dalianis T. Intense CD44 expression is a negative prognostic factor in tonsillar and base of tongue cancer. *Anticancer Res* 2012; 32(1):153-61. **IF(2011): 1,725**
19. Pekár Gy, Hofmeyer S, Tabár L, **Tarján M**, Chen H-H, Yen AM, Chiu SH, Hellberg D, Gere M, Tot T. Multifocal breast cancer documented in large-format histology sections. *Cancer* 2013;119(6):1132-9. **IF(2011): 4,771**

Abstracts:

1. **Tarján M**, Cserni G. Esophagogastric varices - is there a relationship between their rupture and vessels of the ligamentum falciforme hepatis or changes of the seasons? *Virchows Archiv* 1999; 435(3):356.

2. Cserni G, Burzykowski T, Vinh-Hung V, Boross G, Sinkó M, Svébis M, **Tarján M**, Bori R, Kocsis L, Rajtar M, Tekle EW, Baltás B. Sentinel node biopsy based factors associated with non-sentinel node involvement in breast cancer. *J Jpn Surg Soc* 2003;104:575.

Presentations:

1. 6th Meeting of Hungarian Urologists in Kecskemét, 15-17 May 1997 (oral presentation) Cserni G, **Tarján M**: Tumoros vagy arra gyanús húgyhólyagminták hisztológiája (1994-1996)- Megoszlás és a leletek első auditja.
2. 1st Bács-Kiskun County Meeting of Young Hungarian Medical Doctors, Kecskemét 14 Nov 1997 (oral presentation) - Molnár B, **Tarján M**: Felnőttkori óriássejtes hepatitis esetismertetés kapcsán.
3. Meeting of Young Pathologists 1998. (oral presentation), Congress of Hungarian Pathologists, Gyula 26-29 Aug 1998 (poster) **Tarján M**: A halálos tüdőembólia és a heveny szívizominfarktus szezonalitása.
4. 5th Congress of Hungarian Group of Thrombosis and Haemostasis, Bükkfürdő, Nov 1998 (poster) **Tarján M**: Tüdőembólia a patológus szemével.
5. 7th Meeting of Hungarian Urologists, Kecskemét, 28-30 May 1999 (oral presentation) **Tarján M**: A férfiak privilégiuma-e a prosztatata?
6. Meeting of Young Pathologists 2000. (oral presentation), **Tarján M**: A colorectalis carcinomák nodalis statusának meghatározása. - A nyirokcsomók lokalizációjának jelentősége
7. Congress of Hungarian Pathologists, Eger, 21-24 Sept 2000 (poster) **Tarján M**: Malignus fibrosus histiocytoma vesében

8. Congress of Hungarian Pathologists, Kaposvár, 30 Aug-2 Sept 2001 (poster) **Tarján M:** Az AGUS klinikai jelentősége
9. Meeting of Young Pathologists, Győr, 2002 (oral presentation) **Tarján M:** Tüdőembólia profilaxis a kórházunk gyakorlatában
10. Congress of Hungarian Pathologists, Siófok, Sept 2004, (poster) **Tarján M:** Egy ritka uterus malignoma: Adenosarcoma endometrii
11. Europrevent Congress, 6-9 May 2009, Stockholm (poster) Tarján J, **Tarján M :** Correlation between the severity of atherosclerosis in coronary and carotid arteries in autopsy verified study.

Table of contents

LIST OF FIGURES.....	9
LIST OF TABLES.....	10
LIST OF ABBREVIATIONS.....	11
1. INTRODUCTION	12
2. AIMS.....	18
3.3 PATIENTS AND METHODS.....	18
3.1 Study population.....	18
3.2 Histological examination.....	19
3.3 Immunohistochemistry.....	24
3.4 Statistical analysis of the biomarker study.....	26
3.5 Statistical analysis of the ECE study.....	27
3.6 Ethics.....	27
4. RESULTS.....	27
4.1 Comparison of DAP with AAP.....	27
4.2 Analysis of potential biomarkers of poor prognosis.....	29
4.3 Prediction of ECE	34
5. DISCUSSION.....	39
6. SUMMARY, CONCLUSIONS.....	48
ACKNOWLEDGEMENTS.....	49
REFERENCES.....	50
SUPPLEMENTS.....	58

LIST OF FIGURES

- **Figure 1.** The distribution of the incidence and mortality of malignant tumours in Hungary and in Sweden. (page 13.)
- **Figure 2.**Incidence and mortality rates of PCa in Sweden between 1960-2008. (page 14.)
- **Figure 3.** Large-section histology image of a prostate slice with three positive core biopsies and three negative cores. (page 20.)
- **Figure 4.** The basic growth patterns in acinar and ductal (cribriform , papillary and PIN-like, and solid) prostate cancers. (page 21.)
- **Figure 5.** Thick large-format (3D) histology section of a prostatectomy specimen (a); the corresponding two-dimensional (2D) large-format slide (b); comedo growth pattern in DAP in 3D (c) and 2D (d) histology; papillary DAP in 3D (e) and 2D (f) histology; pure cribriform growth pattern in DAP in 3D (g) and 2D (h) histology; AAP for comparison, 3D (i) and 2D (j) histology. (page 23.)
- **Figure 6.** Immunohistochemical p53 expression: absent in AAP (a), present in DAP (b); chromogranine A expression: few positively stained cells in AAP (c), numerous in DAP (d); EGFR expression absent in the AAP (e), present in DAP (f). (page 32.)
- **Figure 7.** Receiver operating characteristic (ROC) curve for the discriminatory power of the combined biomarkers Chromogranin A, EGFR and p53 percentage. (page 34.)
- **Figure 8.** Side-for-side (168 sides) analysis of at least sextant biopsies showing a significant association between the number of positive biopsy cores per side and the finding of ECE at RP. (page 35.)
- **Figure 9.** Dominant side (84 sides) analysis demonstrating an association between the number of positive biopsy cores per side and finding of ECE at RP. (page 36.)
- **Figure 10.** Relationship between the preoperative PSA level and the presence of ECE at RP (page 38.)
- **Figure 11.** Relationship between the biopsy Gleason score and the presence of ECE at RP (page 38.)
- **Figure 12.** Relationship between the combination of three prognostic parameters (number of positive biopsies, preoperative PSA level and biopsy Gleason score) and

the presence of ECE at RP. The high-risk parameters are: number of positive biopsies >1; Gleason score 7 or more; serum PSA > 10 ng/ml. (page 39.)

LIST OF TABLES


- **Table 1.** Prognostic factors for prostate cancer: College of American Pathologists (CAP) and World Health Organization (WHO) (page 15.)
- **Table 2.** List of primary antibodies used in the present study and the basic technical parameters. (page 25.)
- **Table 3.** The clinical and pathological characteristics of the prostate cancer patients according to the presence or absence of a ductal component (page 28.)
- **Table 4.** Unadjusted and adjusted odds ratios of immunohistochemical markers to distinguish pure acinar adenocarcinoma (AAP) of the prostate from ductal/mixed ductal-acinar type adenocarcinoma (DAP) of the prostate on the basis of 110 total prostatectomy specimens. (page 30.)
- **Table 5.** The predictive value of the three selected biomarkers in 24 preoperative core biopsy cases (page 33.)
- **Table 6.** Results of the side-for-side analysis in predicting ECE. (page 37.)
- **Table 7.** Results of the dominant side analysis in predicting ECE. (page 37.)
- **Table 8.** Survey of DAP related literature from PubMed including papers published between 1982 – 2011. (page 41.)
- **Table 9.** Risk groups of prostate cancer, based on the correlation between preoperative diagnostic parameters and 10-year cancer-free survival after RP according to D`Amico (page 46.)

LIST OF ABBREVIATIONS

3D	three dimensional
AAP	acinar adenocarcinoma of the prostate
AMACR	alpha-methylacyl-coenzyme A racemase
ASR	age-standardized rate
AUC	area under the curve
CAP	College of American Pathologists
DAP	ductal adenocarcinoma of the prostate / adenocarcinoma of the prostate with ductal component
ECE	extracapsular extension
EGFR	epidermal growth factor receptor
NED	neuroendocrine differentiation
PCa	prostate cancer
PIN	prostatic intraepithelial neoplasia
PSA	prostate specific antigen
PSAP	prostate-specific acid phosphatase
ROC	receiver-operating characteristic
RP	radical prostatectomy
TMA	tissue microarray
WHO	World Health Organization

1. INTRODUCTION

Prostate cancer (PCa) is the most frequently diagnosed cancer of men (899 000 new cases, 13.6% of the total) and the fifth most common cancer overall. Nearly three quarters of the registered cases occur in developed countries (644 000 cases). Incidence rates of PCa vary by more than 25-fold worldwide, the highest rates being in Australia/New Zealand (104.2 per 100,000) (1), Western and Northern Europe, Northern America. This is largely due to the widespread use of non-organized screening with prostate specific antigen (PSA) testing and subsequent biopsy in these regions. Incidence rates are relatively high in certain developing regions such as the Caribbean, South America and sub-Saharan Africa. With an estimated 258 000 deaths in 2008, PCa is the sixth leading cause of death from cancer in men (6.1% of the total) (1). Because PSA testing has a much greater effect on incidence than on mortality, there is less variation in mortality rates worldwide (10-fold) than in incidence rates, and the number of deaths from PCa is almost the same in developed and developing regions. Mortality rates are generally high in predominantly black populations (Caribbean, 26.3 per 100,000 and sub-Saharan Africa, Age-Standardized rates (ASRs): 18-19 per 100,000), very low in Asia (ASR 2.5 per 100,000 in Eastern Asia for example) and intermediate in Europe and Oceania (1). PCa was the first most frequently diagnosed cancer of men in Sweden and it was the third in rank in Hungary after lung and colorectal cancer in 2008. The same ranking could be seen in the mortality data at this time (**Figure 1**).



GLOBOCAN 2008 (IARC) (24.4.2012)

Figure 1. The distribution of the incidence and mortality of malignant tumours in Hungary and in Sweden.

A rapid increase of incidence of PCa has been observed in Sweden since the 1990s while the rate of mortality remained unchanged (**Figure 2**). During the same period, the increase of incidence in Hungary was less marked than in Sweden, and the mortality rate was lower and stable (1).




Figure 2. Incidence and mortality rates of PCa in Sweden between 1960-2008.

As a result of PSA screening, the majority of patients with PCa are diagnosed with potentially curable disease. Another consequence of screening is that the mean age of patients with this disease has diminished; PCa is no longer a disease of the elderly but is increasingly seen in middle aged men. Furthermore, screening leads to the down-staging of the disease with an increase in the number of organ-confined tumours, curable with radical prostatectomy (RP), a surgical treatment being increasingly offered (2).

Treatment of PCa with RP, radiotherapy and anti-androgen therapy results in prolonged long term survival in patient with localized and androgen-dependent PCa. Various treatment options are currently available for localized disease, including RP, conformal (three-dimensional) external beam radiation, brachytherapy and other types of local therapy (3,4). By contrast, hormone-refractory PCAs are associated with disease relapse and poor survival.

A better understanding of the biological heterogeneity of the disease and reliable prognostic markers are needed to plan the therapy adequately and avoid over- or under-treatment. Prognosis for patients with PCa may be defined as the prediction of future behaviour of

established malignancy, either in the absence of or after the application of therapy (5). Factors associated with outcome may be divided into two categories:

1. Prognostic factors: those that predict relapse or progression independently of future treatment effects.
2. Predictive factors: those that predict response or resistance to a specific treatment.

Currently, there are no predictive factors or markers utilized in PCa. For example, unlike breast carcinoma oestrogen receptor status, which can be used to predict response to hormonal treatment with tamoxifen, androgen receptor status in prostatic carcinoma does not predict response to hormonal therapy. Here, we briefly focus on prognostic factors, with stratification into categories of established factors recommended for routine reporting (category I), factors with promise or recommended despite incomplete data (category II), and factors that are not currently recommended due to insufficient evidence (category III) (**Table 1.**) (6,7).

Category I: Recommended for routine reporting (7)
TNM based stage
Histological grade (Gleason)
Surgical margin status
Perioperative serum PSA
Category II: Factors with promise or recommended despite incomplete data
DNA ploidy
Histologic type
Tumour amount in needle biopsy tissue
Tumour amount in RP specimens (<i>correlates with extracapsular disease</i>)
Category III: Not recommended due to insufficient evidence
Genetic markers
Neuroendocrine markers
Proliferation markers, apoptosis
Perineural invasion
Vascular/lymphatic invasion
Microvessel density
Nuclear morphometry
Androgen receptors
Age

Table 1. Prognostic factors for prostate cancer: College of American Pathologists (CAP) and World Health Organization (WHO) (6)

Category I histopathological factors include pathologic stage and surgical margin status of radical prostatectomy specimens, and Gleason histological grade in all prostatic tissue samples. The best established prognostic parameter, the Gleason score is a widely accepted scoring system, the prognostic significance of which has been repeatedly proven (8), but it is also subject to considerable inter-observer variability, indicating the need for additional or alternative prognostic parameters.

Category II factors that are recommended for reporting include histologic subtypes of PCa and tumour amount in needle biopsy and RP specimens. The tumour amount in needle biopsy tissue may be reported in quantities such as the number of positive cores out of total number of cores, total length (mm) of tumour in all cores, greatest percentage of a single core involved by carcinoma, and total or overall percentage of biopsy tissue involvement (which can be assessed by simple visual inspection). Data exist to suggest that it may be relevant to report more than one measure of tumour extent in needle biopsy tissue (9,10). For RP specimens, it has been recommended to report tumour size as a percentage of cancer in the prostate (6). Additionally, one could measure size of a dominant nodule in two dimensions and indicate the number of blocks involved by tumour over the total number of blocks submitted (11). DNA ploidy was also put into category II, but currently it is felt that the data are not compelling enough to warrant its routine use (6). The probability of extracapsular disease most likely correlates with increasing tumour volume (12). The presence of extracapsular extension (ECE) in RP has been shown to have a significant negative impact on both biochemical and clinical failure rates (13). Therefore, accurate prediction of ECE is crucial when planning adequate treatment. Many predictive models using different preoperative parameters have been developed to promote this process (14-16). Number of positive (tumour-containing) biopsies and percent of cores containing cancer in prostate biopsy may be useful clinical parameters in identifying patients at high risk for ECE (17,18).

Category III factors are not currently recommended for reporting due to insufficient evidence.

The prognostic significance of ductal differentiation in PCa was shown in a number of recent studies, indicating that tumours exhibiting this feature are more aggressive than their conventional acinar counterparts (19-23). Ductal adenocarcinoma of the prostate (DAP) is rare in its pure form and accounts for 0.4–1% of PCAs (24), but focal ductal differentiation in common acinar PCa is observed in up to 5% of radical prostatectomy specimens (25). The

proportion of tumour showing ductal differentiation that confers a prognostic difference remains controversial, but it is becoming more and more evident that identifying ductal differentiation in PCa and delineating these cases from pure acinar adenocarcinoma of the prostate (AAP) is an essential diagnostic task (19-21).

The role of immunohistochemistry in the diagnosis, differential diagnosis and prognostication of PCa is well documented in the literature, although it is mainly limited to prove the infiltrative nature of the lesions and/or their prostatic origin (26-28). The role of immunohistochemical markers in distinguishing different subtypes of PCa is a less explored area. Some reports indicate that neuroendocrine differentiation (NED) in the tumour is a significant prognostic parameter associated with shortened survival after endocrine therapy (29-31). A number of studies have analysed Ki67, p53, or bcl-2 expression in PCa, mostly in the context of prognosis (32-34). DAP expressing PSA and prostate-specific acid phosphatase (PSAP) may also show residual staining for high molecular weight cytokeratins and p63, and 70% express alpha-methylacyl-CoA racemase (AMACR) (24). These immunohistochemical features are, however, very similar to those in AAP, and are of no diagnostic value in distinguishing tumours showing ductal differentiation from pure AAP.

Our department's experience with large format thick histology sections (subgross, "three dimensional" /3D/ pathology) of breast tissue during the past two decades has confirmed the ability of this technique to reliably differentiate between acinar (lobular) and ductal structural components of normal and pathologic breast tissue (35-37). Although the subgross (3D) histology technique has been used to study diseases of the prostate (38), we have found no reports using this technique to determine the ductal or acinar origin or differentiation of prostate cancer. Having to distinguish DAP from AAP, we studied 3D thick section histology of prostatectomy specimens in addition to reviewing all the archived standard histological material.

2. AIMS

The aims of the thesis are as follows:

- 2.1** to evaluate whether patients with PCa exhibiting ductal differentiation (DAP) have an unfavourable prognosis compared to those with pure AAP;
- 2.2** to evaluate the expression of nine immunohistochemical markers as prognostic predictors and their value in delineating carcinomas with and without ductal differentiation;
- 2.3** to refine the histological methodology for discriminating between DAP and AAP and explore whether these results have any therapeutic consequence;
- 2.4** to evaluate the clinical utility of transrectal ultrasound-guided systematic sextant or octant biopsies in the prediction of ECE at RP;
- 2.5** to find a useful combination of prognostic parameters in planning adequate therapy.

3. PATIENTS AND METHODS

3.1 Study population

The study population consisted of 110 patients treated with RP at Falun Central Hospital, Sweden, between January 2000 and December 2006. In 21 of these cases bilateral pelvic lymphadenectomy was also performed. Each patient underwent preoperative examinations according to a standardized protocol for preoperative disease staging. All PCAs were considered to be organ-confined at the time of RP.

The following additional information was collected and analysed for this study: preoperative, postoperative and most recent serum PSA values, the adjuvant therapeutic regimens used, including hormone therapy, total androgen blockade, administration of radiotherapy and/or chemotherapy. Recurrence of the disease in this study was defined as histologically proven

local recurrence, loco-regional lymph node recurrence, development of distant metastases or biochemical recurrence (PSA level \geq 0.2 ng/ml) (39).

In an earlier phase of the study (January 2000- August 2005) we analysed 84 cases with ultrasound-directed systematic sextant (three biopsies per side; i.e. apex mid gland, base) biopsies in 60 cases and systematic octant (four biopsies per side; ie, apex, mid-lateral and mid-medial gland, base) biopsies in 24 cases.

3.2 Histological examination

The prostatectomy specimens were histologically evaluated using multi-level large-format whole-mount cross-sections over the entire specimen (3 to 8 large-format blocks per case). Our large-section histology technique employs standard 10x8 cm object glasses while the size of the paraffin blocks is adjusted to the size of the prostatectomy specimens. This enables assessment of tumour multifocality, individual lesion size, capsular involvement (ECE) and also involvement of the seminal vesicles, which are included with the entire prostate gland on the sections (**Figure 3**). The complete material (84 preoperative biopsies and 110 prostatectomy specimens) was retrospectively reviewed.



Figure 3. Large-section histology image of a prostate slice with three positive core biopsies (top row) and three negative cores (lower row).

Histological variables obtained from the prostatectomy specimens included histological tumour type (DAP or AAP), Gleason score, size measurement of the excised prostate and of the individual tumour foci, determination of the number of tumour foci, evaluation of the surgical margins, presence of ECE, vascular invasion, seminal vesicle invasion and description of the presence or absence of high-grade prostatic intraepithelial neoplasia (PIN). Ductal differentiation in the tumours was established on the basis of cellular characteristics and histological growth patterns, as described in the literature (40). The ductal parts of the tumour were composed of tall columnar cells (in contrast to cuboidal cells of the acinar cancers). The following growth patterns were regarded as typical of ductal differentiation: papillary, cribriform, and solid. Typical images illustrating the morphological criteria are shown in **Figure 4**.




Figure 4. The basic growth patterns in acinar (A) and ductal (cribriform [B], papillary and PIN-like [C], and solid [D]) prostate cancers (H&E 100X). Inserts with high power magnification details from the same tumours.

Each case was analysed using a subgross, 1,500 micron thick 3D section technique: the paraffin block was melted in an incubator, the specimen was then placed into a series of xylene baths over a 24-hr period in order to complete the deparaffinization. After rehydration the tissue was stained with Harris haematoxylin and immersed in methyl salicylate for clarification. Low-power stereoscopic microscopy (5-10X magnification) was used to view the specimen while immersed in methyl salicylate (37).

Morphological criteria for evidencing ductal differentiation within a tumour in large format thick (3D) sections were: presence of large contorted cancer-filled ducts found in the periurethral or, unusually, in subcapsular location, associated with or in close proximity to the acinar part of the cancer; or presence of innumerable duct-like structures observed in large areas of the prostate, within the tumour and also in the adipose tissue surrounding the prostate (a rare finding). Typical cases of DAP and AAP are illustrated in **Figure 5**.

Pure DAP and mixed ductal-acinar carcinomas were grouped together (they appear as DAP through the text). The extent of ductal differentiation within the tumour was not analysed.




Figure 5. Thick large-format (3D) histology section of a prostatectomy specimen (a); the corresponding two-dimensional (2D) large-format slide (b); comedo growth pattern in DAP in 3D (c) and 2D (d) histology; papillary DAP in 3D (e) and 2D (f) histology; pure cribriform growth pattern in DAP in 3D (g) and 2D (h) histology; AAP for comparison, 3D (i) and 2D (j) histology.

3.3 Immunohistochemistry

Tissue microarray (TMA) blocks were constructed using archival formalin-fixed, paraffin-embedded RP specimens from all 110 patients. Two 2 mm cores were taken from the area of the tumour showing the predominant Gleason pattern of the invasive cancer or from the ductal area, if present. Sections of 3.5 μm were cut from the TMA blocks. The TMA slides were immunostained in the Ventana autostainer (Ventana Benchmark XT and Ultra) using Ventana UltraView DAB (760-500). The Ventana stainer uses a multimer cocktail of goat anti-rabbit and goat anti-mouse for the detection system, and horseradish peroxidase conjugate for the visualization of DAB solution. The slides were incubated with diaminobenzidine (DAB) as the chromogene for 10 minutes then counterstained with haematoxylin (Ventana 760-2021) and Bluing Reagent (760-2037) for 4 min. Slides were washed in hot tap water with detergent (YES) then washed in distilled water for 5 min, dehydrated through graded alcohols to xylene baths, and mounted in Pertex organic mounting medium (Histolab, Gothenburg, Sweden). The primary antibodies used are listed in **Table 2**.

Antibody	Major function	Ref. number	Clone	Species	Dilution	Antigen retrieval	Source	Inst.
Ki-67 lot:00062416	Proliferation	M7240	MIB-1	mouse	1:100	CC1 mild 30 min	DAKO	XT
p53 lot:668526	Tumour suppression	800-2912	DO-7	mouse	RTU	CC1 mild 30 min	Ventana	XT
p16 lot:H2109	Tumour suppression	SC-1207	-	rabbit poly	1:25	CC2 mild 36 min	Santa Cruz	Ultra
p27 lot:038(501)	Tumour suppression	M7203	SX53G 8	mouse	1:25	CC1 mild 30 min	DAKO	XT
Cox-2 lot:00034	Inflammation , decreased apoptosis	M3617	CX-294	mouse	1:50	CC1 mild 30 min +amplifying	DAKO	XT
EGFR Lot: 00038049	Proliferation	M7239	-	mouse	1.50	Protease1; 8 min	DAKO	XT
Tenascin-C lot:0129A	Matrix protein	M0636	DAKO-TN2	mouse	1:50	Protease1; 8 min	DAKO	XT
Chromogranine A lot:00011085	NE marker	M0869	DAKO-A3	mouse	1:1500	CC1 mild 30 min	DAKO	XT
bcl-2 lot:29108	Increased apoptosis	760-4240	124	mouse	RTU	CC2 mild 36 min +amplifying	Ventana	Ultra

Table 2. List of primary antibodies used in the present study and the basic technical parameters.

(Inst.: Instrument; CC1: antigen retrieval solution, type 1; CC2: antigen retrieval solution, type 2; NE: neuroendocrine; RTU: ready to use (prediluted); XT: Ventana Bench Mark XT immunohistochemistry instrument; Ultra: Ventana Bench Mark Ultra immunohistochemistry instrument)

All biopsies were evaluated with all antibodies. The percentage of tumour cell nuclei stained for Ki-67, p53, p16, p27, and bcl-2 were counted, and a cut-off value of 10% used to distinguish high- and low-expression cases. Chromogranine A expression was estimated using a semi-quantitative scoring system based on the number of chromogranine A positive cells in a “hot spot” area at 400 × magnification (0, negative; 1, 1–4 positive cells; 2, 5–19 cells; and 3, staining in ≥ 20 cells). For Cox-2 the intensity of staining was estimated on a four-grade scale (0, absent; 1, weak; 2, moderate; and 3, strong). The staining intensity of tenascin C was assessed in both the stromal and periglandular areas (0, negative/normal staining; 1, weak/moderate staining; and 2, strong staining). Membranous immunoreactivity for epidermal growth factor receptor (EGFR) was categorized as undetectable (0), staining in less than 10% of tumour cells or as faint incomplete membrane staining in more than 10% of the tumour cells (1), weak to moderate, complete membrane staining in more than 10% of tumour cells (2), and intense complete membrane staining in more than 10% of tumour cells (3).

3.4 Statistical analysis of the biomarker study

The Chi-square test was used to assess the relationship of each biomarker to AAP and to DAP. The Fisher’s exact test was adopted, if the expected number of cases was less than 5. We also adopted the logistic regression model to estimate the odds ratios for each biomarker indicating DAP or AAP. The biomarkers shown to be significant in univariate analysis were evaluated in multivariate logistic regression in order to select the most significant biomarkers. The receiver-operating characteristic (ROC) curve was used to assess the discriminatory power of the three selected biomarkers (see later). The area under the curve (AUC) and its 95% confidence interval were calculated according to Hanley (41). We tested the preoperative discriminative ability of three selected biomarkers to predict the risk of DAP among 24 preoperative core biopsy samples from 110 cases and adjusted to the baseline risk of the 24 test cases on eight different combinations of the three biomarkers. The entire material was followed up until August 31, 2010, giving a mean follow-up time of 5.1 years (60.9 months, standard deviation 21.2).

3.5 Statistical analysis of the ECE study

The presence or absence of ECE, defined as penetration of the tumour beyond the capsule of the prostate, was correlated with the number of positive (tumour-containing) needle biopsies (none, one, two or three) using Chi-square test. The data were analysed in two different ways to determine the value of at least sextant needle biopsies in the prediction of ECE. First, a side-for-side analysis was performed in the 168 prostatic sides (84 cases) available in this series. The number of positive needle biopsies on each side (none, one, two or three) was correlated with the presence or absence of ECE at RP. Secondly, for each patient, a dominant-side analysis was performed to assess the utility of systematic needle biopsies in predicting ECE in the side containing the greatest tumour volume. In this analysis, the number of positive needle biopsies (one, two or three) in the dominant lobe was correlated with the presence or absence of extracapsular disease. In these cases we calculated the sensitivity, specificity, and the negative and positive predictive values of the number of involved preoperative core biopsies in predicting ECE.

The preoperative PSA levels as well as the biopsy Gleason score was also registered in every case. PSA levels higher than 10 ng/ml and Gleason score higher or equal to 7 were regarded as high-risk parameters and were also tested as individual parameters and in combination with the number of positive cores.

3.6 Ethics

The study was approved by the Regional Ethical Committee of the Uppsala-Örebro Health Care Region, Sweden (Dnr:2010/087). All surviving patients gave written consent for the use of the prostate histology samples for research purposes.

4. RESULTS

4.1. Comparison of DAP with AAP

The subgross (3D) histology specimens together with routine large format histology slides demonstrated focal ductal differentiation in 12 cancers (mixed ductal-acinar cases) and evidenced one case of pure DAP. The remaining 97 cases were AAPs. **Table 3** summarizes

the clinical and pathological characteristics of cases of pure AAPs (97/110;88%) and DAPs (13/110;12%).

Parameter	Acinar adenocarcinoma (AAP)	Ductal/mixed ductal-acinar adenocarcinoma (DAP)	p-value
Number of cases	97/110 (88%)	13/110 (12%)	
Mean patient age (years)	61.95 (38-78)	63.08 (52-69)	0.5793
Positive digital rectal examination	35/97 (36%)	10/13 (77%)	0.0049
Size (mm) of prostate measured by transrectal ultrasound	28.4 (15-102)	34.6 (22-60)	0.0021
Preoperative PSA level, ng/ml	8.04 (2.1-26)	8.97 (3.7-19)	0.4869
Postoperative PSA level \geq 0.2 ng/ml	0.49 (0.22-1)	0.75 (0.20-1.30)	0.4143
Number of pT2 cases	71/97 (73%)	2/13 (15%)	<0.0001*
Number of pT3a and pT3b cases	23/97 (24%)	8/13 (61%)	
Number of pT3c cases	3/97 (3%)	2/13 (15%)	
Number of pT4a cases	0/97	1/13 (8%)	
Cases with a single tumour focus	5/97 (5%)	1/13 (8%)	0.3459*
Cases with 2-4 tumour foci	69/97 (71%)	7/13 (54%)	
Cases with >5 tumour foci	23/97 (24%)	5/13 (38%)	
Cases with the largest tumour focus 1-19 mm	55/97 (56%)	3/13 (23%)	0.0020*
Cases with the largest tumour focus 20-39 mm	42/97 (43%)	8/13 (62%)	
Cases with the largest tumour focus \geq 40 mm	0/97	2/13 (15%)	
Disease extent, mm	36.49 (10-53)	41.54 (21-70)	0.0605
Presence of high grade PIN	52/97 (54%)	12/13 (92%)	0.0079
Cases with Gleason score <6	13/97 (14%)	0/13	<0.0001*
Cases with Gleason score =6	42/97 (43%)	0/13	
Cases with Gleason score =7	35/97 (36%)	8/13 (62%)	
Cases with Gleason score >7	7/97 (7%)	5/13 (38%)	
Cases with a positive surgical margin	16/97 (16%)	6/13 (46%)	0.0219*
Cases with extracapsular extension	25/97 (26%)	11/13 (84%)	<0.0001*
Cases with vascular invasion	6/97 (6%)	5/13 (38%)	0.0033*
Cases with seminal vesicle infiltration	3/97 (3%)	3/13 (23%)	0.0213*
Cases with biochemical/local recurrence	11/97 (11%)	8/13 (62%)	<0.0001*
Cases with locoregional lymph node metastases	0/97	2/13 (15%)	
Cases with distant metastases	0/97	3/13 (23%)	
Cases with prostate cancer death	0/97	1/13 (8%)	0.1508*
Cases with death from other disease	3/97 (3%)	0/13	
Cases with adjuvant radiotherapy	14/97 (14%)	6/13 (46%)	0.0020*
Cases with adjuvant hormonal therapy	4/97 (4%)	4/13 (31%)	0.0109*
Cases with adjuvant total androgen blockage	0/97	3/13 (23%)	0.0013*
Cases with adjuvant chemotherapy	0/97	1/13 (8%)	0.1182*

Table 3. The clinical and pathological characteristics of the prostate cancer patients according to the presence or absence of a ductal component. Data are shown as n/N (%) or mean (range). * Fisher exact test

The DAP cases had a significantly greater frequency of the following parameters: positive digital rectal examination ($p=0.0049$), mean prostate size measured by transrectal ultrasound ($p=0.0021$), pT3a and more advanced cancers ($p<0.0001$), largest tumour focus >20 mm ($p=0.0020$), high grade PIN ($p=0.0079$), Gleason score ≥ 7 ($p<0.0001$), positive surgical margin ($p=0.0219$), ECE ($p<0.0001$), vascular invasion ($p=0.0033$), seminal vesicle infiltration ($p=0.0213$), biochemical/local recurrence, regional lymph node metastases, distant metastases ($p<0.0001$). The AAP cases had a significantly greater frequency of the following parameters: case frequency, pT1 and pT2 cases ($p<0.0001$), largest tumour focus <20 mm ($p=0.0020$) and Gleason score ≤ 6 ($p<0.0001$). There was no statistically significant difference in the patients' age at the time of prostatectomy, preoperative and postoperative PSA levels, and number of tumour foci or disease extent.

Although all of the cases were clinically organ-confined at the time of RP, histologic examination confirmed that only 15% (2/13) of the DAP cases and 73% (71/97) of the AAP cases were organ confined. Of the 21/110 patients who were selected for bilateral pelvic lymphadenectomy, metastases were found in two, both of which were DAP cases.

The outcome measures were all consistently poorer for DAP. During the average follow-up time of 5.1 years (range 4-10 years) all 13 DAP cases had evidence of disease progression: biochemical or local recurrence in 8 cases, distant metastases in 3 cases (one of whom died of the disease), lymph node metastases in 2 cases. In contrast, there was no evidence of disease progression in 86 (89%) of the 97 AAP cases. Disease progression was limited to biochemical recurrence only in the remaining 11 (11%) of these 97 cases, all 11 of which had a considerable tumour burden, with the largest tumour focus measuring at least 25 mm or being extensively multifocal. Among the 97 AAP cases, three patients died of unrelated causes during the follow-up period.

4.2 Analysis of potential biomarkers of poor prognosis

Table 4 shows the unadjusted and adjusted odds ratios for the ability of biomarkers to discriminate PC of acinar versus ductal origin in the total prostatectomy specimens.

Biomarkers	AAP No.(%)	DAP No.(%)	Unadjusted Odds Ratio	Univariate 95% CI	Adjusted Odds Ratio	Multivariate 95% CI
Ki67						
1-9%	71(94.7)	4 (5.4)	1			
≥10%	25 (73.5)	9 (26.5)	6.39	(1.81-22.59)*		
Chromogranine A						
Neg or <4 cells	78 (95.1)	4 (4.9)	1		1	
≥5 cells	18 (66.7)	9 (33.3)	9.75	(2.7-35.22) *	11.56	(2.04-65.31)
Tenascin stroma						
Normal/weak	91(90.1)	10 (9.9)	1			
Moderate/strong	5 (62.5)	3 (37.5)	5.46	(1.13-26.33) *		
Tenascin Periglandular						
Normal	24 (100)	0 (0)	1			
Weak/moderate/strong	72 (84.7)	13 (15.3)	4.35 ⁺	(1.05-17.02) ⁺		
EGFR						
10%membrane staining >=10%incomplete membrane staining	92 (92.9)	7 (7.1)	1		1	
≥10% weak, moderate / strong membrane staining	5 (45.4)	6 (54.6)	15.77	(3.84-64.84)	11.25	(1.71-74.10)
p53						
Neg/≤9%	85 (96.6)	3 (3.4)	1		1	
≥10%	12 (54.6)	10 (45.5)	23.61	(5.86-98.15) *	20.83	(3.71-116.94)
p27						
Neg. or ≤9%	68(88.3)	9(11.7)	1			
≥10%	28(87.5)	4(12.5)	1.08	(0.31-3.8)		
Cox-2						
Neg./Weak	75(90.4)	8(9.6)	1			
Moderate/Strong	21(80.8)	5(19.3)	2.23	(0.66-7.54)		
p16						
Neg/≤9%	53(93.0)	4(7.0)	1			
≥10%	44(83.0)	9(17.0)	2.71	(0.78-9.4)		
bcl-2						
Neg/≤9%	94(89.5)	11(10.5)	1			
≥10%	3(60)	2(40)	5.70	(0.86-37.9)		

Table 4. Unadjusted and adjusted odds ratios of immunohistochemical markers to distinguish pure acinar adenocarcinoma (AAP) of the prostate from ductal/mixed ductal-acinar type adenocarcinoma (DAP) of the prostate on the basis of 110 total prostatectomy specimens. *p value<0.001; ⁺ Exact method

According to the previously described criteria, 26% (25/97) of AAP cases expressed Ki67 in 10 percent or more of tumour cell nuclei, 18% (18/97) were chromogranine A positive, 5% (5/97) EGFR positive, 12% (12/97) p53 positive, 5% (5/97) expressed tenascin C in the tumour stroma, and 74% (72/97) showed periglandular tenascin C overexpression. The corresponding numbers for DAP were 69% (9/13), 69% (9/13), 46% (6/13), 77% (10/13), 23% (3/13), and 100% (13/13), respectively. No statistically significant differences were seen in p27, cox-2, p16 and bcl-2 expressions.

At multivariate (adjusted) analysis, three of the biomarkers studied provided the most significant discriminatory power: 12-fold for Chromogranine A (aOR=11.56; 95% CI:2.04-65.38), 11-fold for EGFR (aOR=11.25; 95% CI:1.71-74.10), 21-fold for p53 percentage (aOR=20.83; 95% CI:3.71-116.94). Typical reactions in DAP and AAP cases are illustrated in **Figure 6**. A combination of these three biomarkers made it possible to distinguish between the DAP and AAP cases with an accuracy of 94% (AUC 0.94; 95% CI: 0.88-0.99).




Figure 6. Immunohistochemical p53 expression: absent in AAP (a), present in DAP (b); chromogranine A expression: few positively stained cells in AAP (c), numerous in DAP(d); EGFR expression absent in the AAP, present in the normal glands (e), and present in DAP (f).

Table 5 demonstrates the results of testing the predictive value of the three selected biomarkers (Chromogranine A, EGFR, and p53 percentage) on the preoperative core biopsy tissue samples of 12 known DAP (each contained a characteristic pattern that resembled the ductal component) and 12 known AAP cases. The risk for a case being DAP increased with the number of positive biomarkers, being almost 100% for patients with three, followed by

91% to 95% for those with any two, 46% to 61% for those with any single biomarker, and 7% for those with no demonstrable biomarker positivity. We also confirmed that there was no significant difference between the observed and expected number of cases ($\chi^2=1.70$; $p=0.89$), supporting the high predictive value of the three biomarkers. Receiver operating characteristic (ROC) curve for the discriminatory power of these biomarkers is demonstrated in **Figure 7**. (AUC 0.94; 95% CI: 0.88-0.99).

Combinations of biomarkers	EGFR†	Chromogranine A*	P53‡	DAP risk
1	-	-	-	0.0691
2	+	-	-	0.4553
3	-	+	-	0.4620
4	-	-	+	0.6074
5	+	+	-	0.9062
6	+	-	+	0.9457
7	-	+	+	0.9470
8	+	+	+	0.9951

*Chromogranine A: - for negative or <4 cells; + for ≥ 5 cells

†EGFR: - for negative /<10% membrane staining/ $\geq 10\%$ incomplete membrane staining; + for $\geq 10\%$ weak, moderate/strong membrane staining

‡p53 percentage: - for negative/ $\leq 9\%$; + for $\geq 10\%$

Table 5. The predictive value of the three selected biomarkers in 24 preoperative core biopsy cases.

Note: Since these 24 preoperative core biopsy cases may have a different baseline risk compared to the remaining 86 cases, the baseline risk should be adjusted. The risk of DAP was 50% (12/24) in the preoperative dataset, which was higher than the risk of 11.8% (13/110) in the trained dataset. The adjustment is described as follows. The predictive probability of being DAP in the trained dataset (110 samples) was

$$\hat{P} = \frac{e^{Score}}{1 + e^{Score}}$$

$$Score = -4.8883 + 2.4476 \times Chra + 2.4208 \times EGFR + 3.0364 \times p53$$

Given the fact that the frequencies of positive results on Chromogranine A, EGFR, and p53 in the validated dataset are 37.5%, 12.5%, and 45.8%, respectively, substituting these figures into the equation with the probability equal to 0.5 yielded the adjusted intercept of -2.6, which replaces the figure of -4.8883.




Figure 7. Receiver operating characteristic (ROC) curve for the discriminatory power of the combined biomarkers Chromogranin A, EGFR and p53 percentage

4.3 Prediction of ECE

Overall, of the 168 sides analysed, none of the three / four cores contained tumour tissue in 39 cases (23.2 %), only one of three / four in 67 cases (39.8%), two of three / four in 39 cases (23.2 %), and three of three / four biopsies were positive in 23 cases (13.6 %), respectively. Analysis of the 168 prostate sides revealed a significant association between the number of positive needle cores per side and the histopathologic finding of ECE ($p = 0.0003$). Specifically, when 0 to 1 needle core contained tumour tissue, ECE was detected in only 5.1% and 13.4% of prostate sides, respectively. Conversely, when two or three of three / four needle cores were positive ECE was detected in 35.8% and 65.2% of sides, respectively (**Figure 8**).




Figure 8. Side-for-side (168 sides) analysis of at least sextant biopsies showing a significant association ($p=0.0003$) between the number of positive biopsy cores per side and the finding of ECE at RP.

A dominant-side analysis of the same subset of patients again demonstrated a significant association between the number of positive sextant or octant biopsy cores and the presence of ECE (**Figure 9**). ECE was seen in only 5.7% of the sides that preoperatively had one needle core biopsy specimen positive for tumour. In contrast, ECE was seen in 20.6% and 60% of sides that had two or three tumour-positive needle cores preoperatively ($p = 0.008$).




Figure 9. Dominant side (84 sides) analysis demonstrating an association ($p=0.008$) between the number of positive biopsy cores per side and finding of ECE at RP.

To calculate sensitivity, specificity and positive and negative predictive values, it was necessary to define a cut-off value for positive and negative test results for systematic needle biopsy data. As our data indicated that patients with prostate sides containing no or one core positive out of the three or four available were at significantly lower risk of extracapsular disease than those containing two or three positive cores, the finding of no or only one tumour-positive needle cores was defined as a negative test result for ECE. Conversely, as the risk of having ECE in patients with prostate sides giving two or three tumour-positive needle cores was several times higher, this finding was used to indicate a positive test result.

Analysis of the 168 prostate sides revealed that systematic needle biopsies had a positive predictive value of 46.7% and negative predictive value of 89% (**Table 6**).

	No ECE	ECE
0-1 positive biopsy cores	95	11
2-3 positive biopsy cores	33	29

Specificity: 74%

Sensitivity: 72.5%

Negative Predictive Value: 89%

Positive Predictive Value: 46.7%

Table 6. Results of the side-for-side analysis in predicting ECE

Dominant-side (84 sides) analysis test results are shown in **Table 7**. In this case the positive and the negative predictive values were 37% and 94%, respectively.

	No ECE	ECE
1 positive biopsy core	33	2
2-3 positive biopsy cores	31	18

Specificity: 51%

Sensitivity: 90%

Negative Predictive Value: 94%

Positive Predictive Value: 37%

Table 7. Results of the dominant side analysis in predicting ECE

Figure 10 illustrates the presence or absence of ECE in relation to PSA levels, while **Figure 11** shows its relation to the Gleason score. Presence of ECE in relation to the combination of the three analysed parameters (number of positive biopsy cores, preoperative PSA level and biopsy Gleason score) is presented in **Figure 12**.




Figure 10. Relationship between the preoperative PSA level and the presence of ECE at RP




Figure 11. Relationship between the biopsy Gleason score and the presence of ECE at RP




Figure 12. Relationship between the combination of three prognostic parameters (number of positive biopsies, preoperative PSA level and biopsy Gleason score) and the presence of ECE at RP. The high-risk parameters are: number of positive biopsies >1; Gleason score 7 or more; serum PSA > 10 ng/ml.

5. DISCUSSION

DAP was initially described in 1967 as “endometrial carcinoma” because of its histological resemblance to endometrial carcinoma and presumed origin from the verumontanum, a Mullerian structure (42). The initial impression in the pathology literature was that of a truly endometrial tumour arising in a vestigial Mullerian structure. However, subsequent reports on favourable response to orchiectomy (43) and immunohistochemistry (21,44,45) have proven that it is a neoplasm of prostatic origin. Consequently, the term endometrial adenocarcinoma of the prostate is no longer justified.

The most important original articles on DAP are summarized in **Table 8**.

References	Country	Type of the study	Study Period	No. of DAP	Most important message of study
1. Walker et al, 1982 (44)	USA	Case report	1982	1	The immunohistochemical findings and the close association of the adenocarcinoma with the prostatic epithelium of the villous polyp provided evidence that so-called endometrial carcinoma of the prostatic utricle is of prostatic epithelial origin rather than of Mullerian derivation.
2. Bostwick et al, 1985 (45)	USA	Histo.	1968-1982	13	They agree with the suggestion of Walker et al (44) that the term „endometrial” should be abandoned. They prefer to classify these as prostatic adenocarcinomas with endometrioid features. These tumours are clinically more aggressive than previously thought.
3. Epstein et al, 1986 (21)	USA	Histo.	1963-1983	10	They supports the concept of Bostwick et al (45) and Walker et al (44) that prostatic carcinomas with endometrioid features is a morphologic variant of DAP. These tumours have not shown Mullerian nature.
4. Christensen et al 1991(23)	USA	Histo.	1986-1989	15 with RP	DAP-s are in advanced pathologic stage by the time of presentation and have a much higher short-term failure rate after RP than AAP.
5. Millar et al, 1996 (46)	UK	Histo.	1979-1996	16	Patients with DAP had shown good response to hormone therapy and these tumours had a relatively good prognosis.
6. Oxley et al, 1998 (47)	UK	Immuno-histo.	1982-1996	12 6 pure 6 mixed	The percentage of tumours expressing p53 was similar to the percentage published for high grade AAP. The results for Ki-67 suggest that DAP have higher scores than AAP.
7. Bock et al, 1999 (25)	USA	Histo.	1992-1994	17	The only specific feature for DAP is its distinctive site of growth. Papillary and cribriform growth of cancer on needle biopsy should not be considered diagnostic. They recommended to reject the diagnosis of DAP.
8. Brinker et al, 1999 (22)	USA	Histo.	-1998	58	They conclude that DAP seen on needle biopsy implies more advanced cancer with shortened time to progression.
9. Tu et al, 2002 (48)	USA	Clinical	1977-1997	12	PCa patients with penile or testicular metastases have unique clinical and pathological characteristics. Many of these tumours are compatible with a subtype of DAP.
10. Orihuela et al, 2008 (49)	USA	Clinical	1990-2005	17	Contemporary management of localized DAP with radiation and endocrine therapy yields adequate disease free survival. Patients with metastatic DAP respond well to endocrine treatment.
11. Tavora et al, 2008 (50)	USA	Clinical/histo.	1999-2007	28 PIN-like	PIN-like DAP behaved similar to Gleason score 6 AAP.
12. Lotan et al, 2009 (51)	USA	Mol. Pathol.	1984-2005	38	Significantly lower rate of the TMPRSS2-ERG gene fusion in pure DAP compared to AAP indicating a genetic and biologic difference between the two tumour types.
13. Tu et al 2009 (52)	USA	Clinical/histo.	1985-2006	75 with RP	They evaluated 50 mixed and 25 pure DAP. Pure DAP had better prognosis than mixed type of DAP.
14. Lee et al, 2010 (53)	USA	Histo.	1987-2009	10	They reported 10 unique histological patterns of DAP and showed the differential diagnostic difficulties of these tumours.
15. Morgan et al, 2010 (54)	USA	Clinical	1996-2006	371 (0,1%)	Patients with DAP diagnosis are more likely to present with advanced stage cancer. Men with nondistant disease at diagnosis of DAP had 2.2-fold increase in disease specific mortality.
16. Samaratunga et al, 2010 (19)	Australia	Histo.	2004	34 (12,7%)	Twenty-five cases (73%) with DAP had ECE compared to 32.9% of AAP cases. They recommended that any portion of ductal component should be reported in core biopsies specimens.

17. Amin et al, 2011 (20)	USA	Histo.	1995- 2008	93 (0,5%)	DAP admixed with Gleason grade 3 is more aggressive than Gleason score 7 AAP, as long as the ductal component is => 10%. Gleason score 8-10 tumours with ductal features are not significantly more aggressive than AAP Gleason score 8-10 cancers.
18. Finamanti et al, 2011 (55)	Italy	Clinical	1997- 2010	56 (4,5%)	DAP is more likely to present with advanced clinical stage at diagnosis than AAP
19. Meek et al, 2011 (56)	USA	Clinical	1970- 2011	693 (~0,1%)	DAP is associated with a high rate of PCa specific mortality, similar to Gleason 4+4 AAP.
20. Our study 2012	Sweden	Immuno- histo.	2000- 2006	13 (11,8%)	Assessment of chromogranine A, p53, and EGFR in prostate carcinoma may serve as useful adjunctive diagnostic tools for delineating more aggressive prostate cancer cases exhibiting ductal differentiation.

Table 8. Survey of DAP related literature from PubMed including papers published between 1982 – 2011.

DAP, as we have defined it, comprised 11.8% of all tumours in our study, which was based on an unselected consecutive series of 110 patients who underwent RP. This proportion is somewhat higher than the proportion of DAP reported in most previous studies (23,45,46,53,54) although a higher percentage has also been reported (19). We attribute the higher frequency of DAP in our material to the use of subgross (3D) histology in all 110 total prostatectomy samples, because this technique provides better visualization of ductal structures, particularly at the periphery of the prostate, where 12/13 of the DAP tumours were found in our material.

There are many differential diagnostic difficulties when diagnosing DAP on needle biopsies. The most difficult distinction is between cribriform high-grade PIN and DAP. There are several features that may distinguish these two lesions on needle biopsy. DAP often contain true papillary fronds with well-established fibrovascular cores, whereas PIN more frequently shows micropapillary fronds with tall columns of epithelium without fibrovascular stalks. DAP may show stromal fibrosis, haemosiderin deposition or perineural invasion, which would not be seen with PIN. Finally, DAP may consist of very large or back-to-back glands, whereas glands involved by PIN are of the size and distribution of benign glands. We agree with the suggestion of Brinker et al that many of the cases that have been designated as intaductal carcinomas earlier would be now regarded as DAP. Pathologist must be able to

recognize this morphology as being malignant on needle biopsy regardless of the presence of basal cells (22).

Several recent publications indicated a more aggressive clinical course in cases with DAP compared to AAP, in contrast to occasional reports showing no difference between the two (46). A poor 5-year-survival rate, ranging from 15% to 43% was reported by Bostwick et al (45), Christensen et al. (23), Morgan et al. (54) and Samaratunga et al. (19). In the present study, factors that are related to poor prognosis, i.e. tumour stage, high grade PIN, Gleason score, positive surgical margins, ECE, vascular invasion and seminal vesicle infiltration were associated with tumours showing ductal differentiation. As much as 25% to 40% of patients with DAP have metastases at the time of diagnosis (52). In addition, these tumours tend to spread to unusual sites, such as the penis, testis, visceral organs (liver, lungs, brain) and skin (48,57,58). Our results also indicate an unfavourable prognosis in cases showing ductal differentiation; visceral metastasis (1 case), skeletal metastases (2 cases), locoregional lymph node metastases (2 cases), and prostate cancer related death (1 case) were seen exclusively in tumours with ductal differentiation in this study. While some authors indicate that ductal differentiation in less than 10% of the tumour has no prognostic relevance (20), others, similarly to our study, provided evidence to the contrary (19).

Although there are sporadic reports on DAP exhibiting bcl-2 (59) or CK20 (26) in contrast to AAP, we did not find any systematic studies in the literature regarding specific immunohistological marker panel(s) that would reliably distinguish between DAP and AAP. Therefore, we designed the present study to test commercially available, routinely used antibodies in this setting. We found p53, chromogranine A, EGFR and Ki-67 expression of the tumour cells to be associated with ductal differentiation, and therefore as promising potential immunohistochemical markers of this phenotype.

The prostate gland has the largest population of neuroendocrine cells in the male genital tract. Some authors found a correlation between NED in PCa and Gleason score and/or other factors indicating aggressive behaviour (60).

An increased number of neuroendocrine cells have been reported in advanced tumour stages, high-grade versus low-grade tumours, and especially after patients were treated with androgen suppression (29-31). In contrast, other researchers found no correlation (61). In theory, tumours derived from a more mature progenitor cell in the stem-cell hierarchy tend to be

homogeneous and express a monoclonal phenotype, whereas tumours derived from an earlier (more pluripotent) progenitor cell tend to be heterogeneous and exhibit a more mixed phenotype (62). This may explain the presence of NED in some less differentiated PCa, and the association of this differentiation with DAP.

The p53 protein induces cell-cycle arrest at the G1 and G2 checkpoints prior to DNA replication and allows the repair of damaged DNA, but also allows the induction of apoptosis. Mutations in the TP53 gene, resulting in loss of the tumour-suppressing functions of wild type (normal) p53 and gain of oncogenic functions are frequently found in invasive cancers, including PCa. Mutations in the TP53 gene are considered a late event in prostate carcinogenesis, and it is unclear whether wild type p53 is expressed in significant amounts in early-stage cancer. Nuclear positivity for p53 in PCa is associated with higher grade tumours, advanced tumour stages, and predicts a poor prognosis (63), an association which was also found in the present study.

EGFR is a membrane-associated tyrosine kinase, and its activity is regulated by ligand-binding and by interactions with receptors of the EGFR family (64). Once this molecule is phosphorylated, the activated signal is passed down through signaling cascades, activating numerous downstream molecules, what ultimately affects cell division, proliferation and cell migration (64). Abnormal signaling in EGFR-related pathways leads to uncontrolled cell growth and has been reported in many solid tumours such as breast, colorectal, head and neck and pancreatic cancers (64).

The molecular mechanisms responsible for PCa development, progression and hormone-independence are not clear yet. Several findings suggest that alterations of different pathways involving growth factor receptors play a role in this multistep process (65). In particular, EGFR is frequently overexpressed in PCa and this is associated with a more aggressive clinical outcome. EGFR is down regulated at the transcriptional level by androgens in normal prostate tissue but up regulated in prostate malignancy, especially in androgen-independent PCa. EGFR overexpression has also been linked to the transition from androgen-responsiveness to the androgen-independent/hormone-refractory phenotype (66). Di Lorenzo et al. have evaluated by immunohistochemistry the expression of EGFR in three different groups of PCa patients representative of different clinical stages of PCa. EGFR was evaluated as potential prognostic indicator of disease progression. A significant increase in EGFR expression was observed from patients treated with radical surgery alone and not yet exposed

to hormonotherapy (41.4%), to patients who received hormonotherapy as primary therapy before radical prostatectomy (75.9%), and finally to patients with metastatic and hormone-refractory disease (100%) (67). Weber et al. have observed a significant association between EGFR expression and higher Gleason scores and poor outcome (68). It remains to be demonstrated if EGFR therapeutic targeting may optimize patient outcome (69).

Ki-67 is a nonhistone protein that identifies proliferating cells. Ki-67 expression has been considered accurate in fresh-frozen tissue. MIB-1 antibody reacts with parts of the Ki-67 antigen and is expressed in paraffin-embedded specimens. MIB-1 expression is similar to that of Ki-67 and is therefore recommended in paraffin-embedded specimens. Some recent studies of patients treated with RP have revealed a positive correlation between Ki-67 expression and cancer recurrence (70).

The prognostic value of MIB-1 staining on paraffin embedded tissue after radical prostatectomy is, however, still controversial. While some authors have reported a correlation with poor prognosis (71-73), others did not (74,75), but it seems that MIB-1 expression is an independent marker of poor prognosis in the majority of the studies. Interestingly, expression of Ki-67 was less significantly different in the DAP and AAP in our study and therefore it was not within the first three selected biomarkers.

A thorough statistical analysis demonstrated that a combination of chromogranine A, p53 and EGFR expression were reliable predictors of the presence of the ductal/mixed ductal-acinar type PCa in our series of prostatectomy specimens and remained reliable in the preoperative core biopsy series. Although these results are sound, larger studies are needed to confirm the discriminatory power of these biomarkers.

Accurate preoperative prediction of the status of surgical margins is of paramount clinical importance for treatment planning, especially for patients being considered for nerve-sparing procedures and/or preoperative neoadjuvant therapy. Paulson et al (76,77) reported that positive margins were associated with decreased cancer specific and overall survival. The cumulative data suggest that surgical margin status is an important predictor of outcome, which in turn means that the ability for preoperative prediction of ECE has important clinical implications.

To our knowledge, Gancarczky et al's study (17) represents the largest series of data demonstrating that the percentage of biopsy cores containing carcinoma (number of positive cores per total number of cores taken) is a highly significant independent predictor of ECE at the time of RP. In this study of 1510 patients from the Center for Prostate Disease Research database using univariate and multivariate analyses, pre-treatment PSA, biopsy Gleason score and the percentage of positive biopsy cores were the three most significant pre-treatment parameters predicting the margin status at radical prostatectomy, similar to other previous reports (15,16,78-82).

Tigrani et al (83) studied 108 patients who underwent prostatectomy for PCa and found that the number of positive biopsies was the best predictor of margin status. It is not surprising, as it is known that serum PSA can be higher in simple hyperplasia of the prostate than in cases of malignancy. Serum PSA level is more important for diagnosing PCa and for the follow-up of the patients than for predicting the surgical margin status. However, in our study there was certain association between increased preoperative PSA levels and the presence of ECE at radical prostatectomy (see below).

On the other hand, the discordance between the biopsy Gleason score and final Gleason score is well documented (84). Our study also revealed that this discrepancy can be diminished by increasing the number of preoperative biopsies. In cases of sextant biopsies the association with final pathological Gleason score was only 57.6%, while it reached 79.2% in octant biopsies.

Our study showed that transrectal ultrasound-guided systematic at least sextant biopsies can be useful in stratifying patients according to the preoperative risk of ECE. In our study population, the prostate sides that demonstrated two or three positive needle biopsies were at several times higher risk of having ECE than those with no or only one positive core.

Our results calculated for systematic sextant needle biopsies and demonstrated in **Table 6** and **7**, indicate that this test has serious limitations when predicting ECE. Using the finding of two or three tumour-positive biopsy cores out of three (or four) cores taken per side as indicative of extracapsular disease shows a disappointingly low positive predictive value of only 37% and 46.7%, respectively. However, finding no or only one core sample to be positive for tumour accurately predicted the absence of extracapsular disease with a negative predictive value approaching 89% and 94%, respectively.

Recently, wide consensus has been reached upon the role of well-determined Gleason score being a powerful prognostic factor for predicting pathologic stage, biochemical failure, local recurrences and lymph node or distant metastases at RP (14,17,85). It also correlates with

virtually all other adverse pathologic parameters, including tumour volume and inked margin status in radical prostatectomy specimens, serum PSA levels and many molecular markers. Specifically, high Gleason scores (7 or more) are associated with worse prognosis, and Gleason scores 5-6 are usually associated with lower progression rates after definitive therapy (85). In our study, positive association between biopsy Gleason score and the presence of ECE at RP could be demonstrated.

The predictive value of the Gleason score is enhanced when combined with other clinical parameters, including rectal digital examinations and serum PSA levels (14,85).

Furthermore, nomograms have been developed to predict the pathological stage at radical prostatectomy, and disease progression after surgery or radiation therapy. The nomograms typically include pre-treatment variables as clinical stage, biopsy-based Gleason score, serum PSA, amount of cancer in needle biopsies, etc. In Sweden, based on three prognostic parameters the patients are divided into low, moderate and high risk groups (**Table 9**) (86).

Risk group	Preoperative T category	PSA ng/ml	Gleason score	10 years cancer free over living %
Low	T1c-T2a and	≤ 10 and	≤ 6	83
Intermediate	T2b or	10-20 or	7	46
High	$\geq T2c$ or	> 20 or	≥ 8	29

Table 9. Risk groups of prostate cancer, based on the correlation between preoperative diagnostic parameters and 10-year cancer-free survival after RP according to D`Amico (87).

This risk allocation predicts life expectancy and is important for treatment planning. Recently, an increasing number of clinicians have started to require more pathological information (e.g. the number of positive biopsies, percentage of cancer tissue in all biopsies) for their therapeutic decisions. Nomograms are used with increasing frequency in clinical practice by urologists and radiation oncologists to counsel their patients regarding therapeutic options and the potential risk of failure based on the therapy they choose (14,17,88).

The best-known algorithm to predict the pathologic stage of clinically localized prostate cancer is the Hamburg algorithm. This system categorizes patients into three risk groups for lymph node metastases based on the Gleason grade of a systematic sextant biopsy using classification and regression tree analysis (89,90). Because of the anatomic location of the

prostate gland, determination of the lymph node status is not easy. This is only possible with certain radiologic imaging techniques which have lower specificity and are more expensive than histological examination. In other organs such as the breasts, we can get an accurate picture of the lymph node status with the examination of the sentinel lymph nodes (91-97). Although sentinel lymphadenectomy has been pioneered in prostate cancer too and has been described as feasible and potentially allowing unexpected lymphatic drainage and metastatic spread to be discovered (98,99), it has not gained wide acceptance. Briganti et al analysed corresponding prostate biopsy specimens with 278 consecutive prostatectomy specimens that included lymph node dissection (100). These authors concluded that the percentage of positive cores and biopsy Gleason score are the two most informative predictors of a positive lymph node status. They created a preoperative nomogram which had 83% accuracy for predicting lymph node status. The Briganti nomogram was recently validated by Heidenreich et al, who examined 499 biopsy-prostatectomy pairs and concluded that the percentage of positive cores was the most reliable predictor of lymph node metastases (101).

Our results also indicate that combining the number of positive cores with additional parameters as preoperative PSA level and biopsy Gleason score further improves the prediction of ECE. Preoperative PSA levels <10 ng/ml in addition to Gleason score <7 and presence of cancer in no more than one core identified a low-risk patient group with no ECE observed in the present study. The opposite combination (preoperative PSA levels ≥ 10 ng/ml in addition to Gleason score ≥ 7 and presence of cancer in more than one core) identified a group of patients with high risk (77% probability, 10/13) of ECE. These results strongly support that the combination of the above mentioned parameters might be used in therapeutical decision making.

6. SUMMARY, CONCLUSIONS

6.1 Our results confirm the previous observations that tumours with ductal differentiation are associated with adverse prognostic variables and outcome.

6.2 Our detailed immunohistochemical study demonstrated that the expression of p53, chromogranine A and EGFR in tumour cells of prostate cancer can differentiate tumours showing ductal differentiation from purely acinar cancers with reasonable accuracy. Assessing the expression of these biomarkers may represent not only useful ancillary diagnostic tools in prostate pathology, but could also predict a less favourable outcome.

6.3 Both 3-dimensional histology and the three selected biomarkers (combining chromogranine A, EGFR and p53) can help to accurately distinguish DAP from AAP. This discriminatory ability offers AAP cases less radical treatment regimens and emphasizes the need to develop more effective treatment regimens for DAP cases.

6.4 The results of the present study indicate that transrectal ultrasound-guided systematic, at least sextant needle biopsies can be used to assist the prediction of extracapsular disease at radical prostatectomy. Prostate sides giving no or only one PCa containing cores out of the three (sextant biopsy) or four (octant biopsy) are at a relatively low risk of having ECE compared with those containing two or three positive cores. Finding no more than one positive out of three or four cores available per side predicted the absence of extracapsular disease with a negative predictive value approaching 94%.

6.5 Combining this information (see above under 6.4) with preoperative PSA level and biopsy Gleason score further enhances the predictive power for ECE. Such information is useful in planning nerve-preservation at RP.

ACKNOWLEDGEMENTS

I thank my supervisor and previous boss, Professor Gábor Cserni, head of the Department of Pathology, Bács-Kiskun County Teaching Hospital Kecskemét for his support and scientific guidance of my work.

I wish to express my special thanks to my current boss, Professor Tibor Tot, head of the Department of Pathology and Clinical Cytology, Central Hospital, Falun, Sweden, who provided scientific guidance of my work and excellent working conditions for me.

Special thanks are due to Professor László Tabár, Professor Hsiu-Hsi Chen, Wendy Wu, Anna Lenngren , Peter B. Dean and Dan Hellberg who helped this dissertation to be born.

I greatly appreciate all the support and work of high standard provided by laboratory assistants of the Department of Pathology and Clinical Cytology, Central Hospital, Falun, Sweden without whom this task would never have been fulfilled.

I also thank my family and my parents for encouraging and supporting me.

REFERENCES

1. IARC-International Agency for Research on Cancer, Cancer Mondial, Globocan 2008 database.
2. Greenlee RT, Hill-Harmon MB, Thum M. Cancer statistics CA Cancer J Clin 2001;51:15-36.
3. Bahn DK, Lee F. Cryosurgical ablation therapy for prostate cancer. Arch Ital Urol Androl 2000;72:302-4.
4. Kiel HJ, Wieland WF, Rossler W. Local control of prostate cancer by transrectal HIFU-therapy. Arch Ital Urol Androl 2000;72:313-9.
5. Hayes DF, Bast RC, Desch CE, et al. Tumor marker grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
6. Bostwick DG, Grignon DJ, Hammond EH, et al. Prognostic factors in prostate cancer. College of American Pathologists consensus Statement 1999. Arch Pathol Lab Med 2000;124:995-1000.
7. Bostwick DG, Foster CS. Predictive factors in prostate cancer: current concepts from the 1999 College of American pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. Semin Urol Oncol 1999;17:222-72.
8. Egevard L. Reproducibility of Gleason grading of prostate cancers can be improved by the use of reference images. Urology 2001;57:291-5.
9. Lewis. Jr JS, Vollmer RT, Humphrey PA. Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population. Am J Clin Pathol 2002;118:442-50.
10. Bismar TA, Lewis JS, Vollmer RT, et al. Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population. Am J Surg Pathol 2003;27:432-40.
11. Srigley JR, Amin MB, Bostwick DG, et al. Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland. Arch Pathol Lab Med 2000;124:1034-9.
12. Stamey TA, McNeal JE, Freiha FS, et al. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988;139:1235-41.
13. Ohori M, Wheeler TM, Kattan MW, et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995;154:1818-24.

14. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. *JAMA* 1997;277:1445-51.
15. Cheng L, Slezak J, Bregstrall EJ, et al. Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy. *J Clin Oncol* 2000;18:2862-8.
16. Bostwick DG, Qian J, Bergstrall EJ, et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. *J Urol* 1996;155:1361-7.
17. Gancarczyk KJ, Hongyu WU, Mc Leold DG, et al. Using the percentage of biopsy cores positive for cancer, pre-treatment PSA and highest biopsy Gleason sum to predict pathology stage after radical prostatectomy: The center for prostate disease research normograms. *Urology* 2003;61:589-95.
18. Sebo TJ, Bock BJ, Cheville JC, et al. The percent of cores positive for cancer in prostate needle biopsy specimens is a strongly predictive of tumor stage and volume at radical prostatectomy. *J Urol* 2001;163:174-8.
19. Samaratunga H, Duffy D, Yaxley J, et al. Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension. *Hum Pathol* 2010;41:281-5.
20. Amin A, Epstein JI. Pathologic stage of prostatic ductal adenocarcinoma at radical prostatectomy: effect of percentage of ductal component and associated grade of acinar adenocarcinoma. *Am J Surg Pathol* 2011;35:615-9.
21. Epstein JI, Woodruff JM. Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases. *Cancer* 1986;57:111-9.
22. Brinker DA, Potter SR, Epstein JI: Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. *Am J Surg Pathol* 1999;23:1471-9.
23. Christensen WN, Steinberg G, Walsh PC, et al. Prostatic duct adenocarcinoma. Findings at radical prostatectomy. *Cancer* 1991;67:211.
24. Epstein JI. Prostatic ductal adenocarcinoma: A mini review. *Med Princ Pract* 2010;19:82-5.
25. Bock BJ, Bostwick DG. Does prostatic ductal adenocarcinoma exist? *Am J Surg Pathol* 1999;23:781-5.
26. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. *Am J Clin Pathol* 2002;117:471-2.

27. Ljung G, Norberg M, Holmberg L, et al. Characterization of residual tumor cells following radical radiation therapy for prostatic adenocarcinoma; immunohistochemical expression of prostate-specific antigen, prostatic acid phosphatase, and cytokeratin 8. *The Prostate* 1997;31:91-7.
28. Bassily NH, Vallorosi CH, Akdas G, et al. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. *Am J Clin Pathol* 2000;113:383-8.
29. Krijnen JL, Bogdanowicz JF, Seldenrijk CA, et al. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrin therapy. *J Urol* 1997;158: 171-4.
30. May M, Siegsmond M, Hammermann F, et al. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy. *Scand J Urol Nephrol* 2007;41:375-81.
31. Tamas EF, Epstein JI. Prognostic significance of Paneth cell-like neuroendocrine differentiation in adenocarcinoma of prostate. *Am J Surg Pathol* 2006;30: 980-5.
32. Gerdes J, Lemke H, Baish H, et al. Cell cycle analysis of cell proliferation-associated human nuclear antigen defined by monoclonal antibody Ki-67. *Immunol* 1984;133:1710-5.
33. Moul JW, Bettencourt MC, Sesterhenn IA, et al. Protein expression of p53, bcl-2 and Ki-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. *Surgery* 1996;120:159-66.
34. Stapleton AM, Zbell P, Kattan MW, et al. Assessment of the biologic markers p53, Ki-67 and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. *Cancer* 1998;82:168-75.
35. Tot T, Tabár L, Dean PB. The pressing need for better histologic-mammographic correlation of the many variations in normal breast anatomy. *Virch Arch* 2000;437:338-44.
36. Tot T, Tabár L, Dean PB. *Practical Breast Pathology* Stuttgart-New York:Thieme 2002.
37. Tabár L, Tot T, Dean PB. *Breast Cancer: The Art and Science of Early Detection with Mammography. Vol I. Perception, Interpretation, Histopathologic Correlation.* Stuttgart: Thieme; 2005:pp 405-38.
38. Kastendieck H, Altenähr E, Hüsselmann H, et al. Carcinoma and dysplastic lesion of the prostate. A histomorphological analysis of 50 total prostatectomies by step-section technique. *Z Krebsforsch Klin Onkol Cancer Res Clin Oncol* 1976;88:33-54.
39. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological

- Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. *J Urol* 2007;177:540-5.
40. Yang XJ, Cheng L, Helpap B, et al. Ductal adenocarcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn A. World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004.
 41. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology* 1982;143:29-36.
 42. Melicow MM, Pachter MR: Endometrial carcinoma of prostatic utricle (uterus masculinus). *Cancer* 1967;20:1715-22.
 43. Young BW, Lagios MD. Endometrial (papillary) carcinoma of the prostatic utricle-response to orchidectomy. A case report. *Cancer* 1973;32:1293-300.
 44. Walker AN, Mills SE, Fechner RE, et al. "Endometrial" adenocarcinoma of the prostatic urethra arising in villous polyp. A light microscopic and immunoperoxidase study. *Arch Pathol Lab Med* 1982;106:624-7.
 45. Bostwick DG, Kindrachuk RW, Rouse RV. Prostatic adenocarcinoma with endometrioid features. Clinical, pathological, and ultrastructural findings. *Am J Surg Pathol* 1985;9:595-609.
 46. Millar EK, Sharma NK, Lessells AM. Ductal (endometrioid) adenocarcinoma of the prostate: clinicopathological study of 16 cases. *Histopathology* 1996;29:11-19.
 47. Oxley JD, Abbott CD, Gillatt DA, et al. Ductal carcinomas of the prostate: clinicopathological and immunohistochemical study. *Brit J Urol* 1998;81:109-15.
 48. Tu SM, Reyes A, Maa A, et al. Prostate carcinoma with testicular or penile metastases: clinical, pathologic, and immunohistochemical features. *Cancer* 2002;94:2610-7.
 49. Orihuela E, Green JM. Ductal prostate cancer: Contemporary management and outcomes. *Urol Oncol* 2008;26:368-71.
 50. Tavora F, Epstein JI. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: Clinicopathologic study of 28 cases. *Am J Surg Pathol* 2008;32:1060-7.
 51. Lotan TL, Toubaji A, Albadine R, et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. *Mod Pathol* 2009;22:359-65.
 52. Tu SM, Lopez A, Leibovici D, et al. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. *Cancer* 2009;115:2872-80.
 53. Lee TK, Miller JS, Epstein JI. Rare histological patterns of prostatic ductal adenocarcinoma *Pathology* 2010;42:319-24.

54. Morgan TD, Welty CJ, Vakar-Lopez F, et al. Ductal Adenocarcinoma of the prostate: Increased mortality risk and decreased serum prostate specific antigen. *J Urol* 2010;184:2303-7.
55. Finamanti M, Antonelli A, Contessa P, et al. Ductal carcinoma of the prostate: impact on survival and therapeutic controversies of rare tumor. *Urologia* 2011;78:283-7.
56. Meeks JJ, Zhao LC, Cashy J, et al. Incidence and outcomes of ductal carcinoma of the prostate in the USA: analysis of data from the Surveillance, Epidemiology, and End Results program. *BJU Inter* 2011;109:831-4.
57. Copeland JN, Amin MB, Humphrey PA, et al. The morphologic spectrum of metastatic prostate adenocarcinoma to the lung: special emphasis on histologic features overlapping with other pulmonary neoplasms. *Am J Clin Pathol* 2002;117:552-7.
58. Collina G, Reggiani C, Carboni G. Ductal carcinoma of the prostate metastatic to the skin. *Pathologica* 2011;103:50-1.
59. Tulunay O, Orhan D, Baltaci S, et al. Prostatic ductal adenocarcinoma showing bcl-2 expression. *Int J Urol* 2004;11:805-8.
60. Roznovanu SL, Amalinei C, Radulescu D. Molecular mechanisms in hormoneresistant prostate cance. *Rev Med Chir Soc Med Nat Iasi* 2005;109:577-83.
61. Yamada Y, Nakamura K, Aoki S, et al. An immunohistochemical study of chromogranin A and human epidermal growth factor-2 expression using initial prostate biopsy specimens from patiens with bone metastatic prostate cancer. *BJU Int* 2007;99:189-95.
62. Tu SM, Lin S-H, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumours. *Lancet Oncol* 2002;3:508-13.
63. Scholmm T, Iwers L, Kirstein P, et al A Clinical significance of p53 alterations in surgically treated prostate cancer. *Mod Path* 2008;21:1371-8.
64. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. *Cancer gene Ther* 2008;15:413-48.
65. Mimeault M, Batra SK. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. *Carcinogenesis* 2006;27:1-22.
66. Shah RB, Ghosh D, Elder JT. Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence. *Prostate* 2006;66:1437-44.
67. Di Lorenzo G, Tortora G, D'Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. *Clin Cancer Res* 2002;8:3438-44.

68. Weber DC, Tille JC, Combescure C, et al. The prognostic value of expression of HIF1alpha, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy. *Radiat Oncol* 2012;7:66.
69. Vuky J, Porter C, Isacson C, et al.: Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. *Cancer* 2009;115:784–91.
70. Bostwick DG. Practical clinical application of predictive factors in prostate cancer. A review with an emphasis on quantitative methods in tissue specimens. *Analyt Quant Cytol Histol* 2005;1998;20:323-42.
71. Revelos K, Petraki C, Gregorakis A, et al. P27(kip1) and Ki-67 (MIB-1) immunohistochemical expression in radical prostatectomy specimens of patients with a clinically localized prostate cancer. *In Vivo* 2005;19:911-20.
72. Vis A, Noordzij MA, Fitoz K, et al. Prognostic value of cell cycle proteins p27 (kip1) and MIB-1, and the celladhesion protein CD44s in surgically treated patients with prostate cancer. *J Urol* 2000;164:2156-61.
73. Borre M, Stausbol-Gron B, Overgaard J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. *J Urol* 2000;164:716-21.
74. Moul JW. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. *Eur Urol* 1999;35:399-407.
75. Bai XZ, Masters JR, O'Donoghue N, et al. Prognostic markers in clinically localised prostate cancer. *Int J Oncol* 1999;14:785-91.
76. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-T2N0M0 prostatic adenocarcinoma: Long-term results. *J Urol* 1990;144:1180-4.
77. Paulson DF. Impact of radical prostatectomy in management of clinically localized disease. *J Urol* 1994;152:1826-30.
78. Grossfeld GD, Chang JJ, Boering JM, et al. Understaging and undergrading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. *J Urol* 2001;165:851-6.
79. Lee AK, Schultz D, Renshaw AA, et al. Patient selection for prostate monotherapy. *Int J Radiat Oncol Phys* 2001;49:673-7.
80. Ogawa O, Egawa S, Arai Y, et al. Preoperative predictors for organ confined disease in Japanese patients with stage T1c prostate cancer. *Int J Urol* 1998;5:454-8.

- 81.** Gohji K, Okamoto M, Takenaka A, Nomi M, Fujii A. Predicting the extent of prostate cancer using the combination of systematic biopsy and serum prostate specific antigen in Japanese men. *BJU Int* 1999;83:39-42.
- 82.** Peller PA, Young DC, Marmaduke DP, et al. Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy. *Cancer* 1995;75:530-8.
- 83.** Tigrani VS, Bhargava V, Sinohara K, et al. Number of positive systematic sextant biopsies predicts surgical margin status at radical prostatectomy. *Urology* 1999;54:689-93.
- 84.** King CR, Patel DA, Terris MK. Prostate biopsy volume indices do not predict for significant Gleason upgrading. *Am J of Clin Oncol* 2005;28:125-9.
- 85.** Amin M, Boccon-Gibod L, Egevad L, et al. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. *Scand J Urol Nephrol Suppl.* 2005;216:20-33.
- 86.** Adding C, Nilsson A, Hosseini A, et al. Radikal prostatektomi - den botande kirurgiska behandlingen. *Läkartidningen* 2012;109:407-11.
- 87.** D` Amico AV, Whittington R, Malkowicz SB, et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. *J Urol* 2001;166:2185-8.
- 88.** Ohori M, Kattan MW, Koh H, et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. *J Urol* 2004;171:1844-9.
- 89.** Haese A, Epstein JI, Huland H, et al. Validation of biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma. *Cancer* 2002;95:1016-21.
- 90.** Conrad S, Graefen M, Pichlmeier U, et al. Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma. *J Urol* 1998;159:2023-9.
- 91.** Cserni G, Boross G, Baltás B. Value of axillary sentinel nodal status in breast cancer. *World J Surg* 2000;24:341-4.
- 92.** Cserni G. Effect of increasing the surface sampled by imprint cytology on the intraoperative assessment of axillary sentinel lymph nodes in breast cancer patients. *Am Surg* 2003;69:419-23.
- 93.** Cserni G, Amendoeira I, Apostolikas N, et al. Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. *Eur J Cancer* 2003;39:1654-67.
- 94.** Cserni G. Pathological evaluation of sentinel lymph nodes. *Surg Oncol Clin North Am* 2007;16:17-34.

- 95.** Cserni G, Bori R, Sejbén I, et al. A hónalji nyirokcsomók további érintettségére vonatkozó modellek elemzése kisméretű (≤ 15 mm) őrszemnyirokcsomó-áttétes emlőrákokban. *Orv Hetil* 2009;150:2182-8.
- 96.** Cserni G, Bori R, Maráz R, et al. Multi-institutional comparison of non-sentinel lymph node predictive tools in breast cancer patients with high predicted risk of further axillary metastasis. *Pathol Oncol Res* 2013;19:95-101.
- 97.** Tarján M. Sentinel lymph node biopsy in Hungary. Results with a revolutionary new method in surgical oncology *Magy Onkol* 2002;46:315-21.
- 98.** Wawroschek F, Vogt H, Weckermann D, et al. The sentinel lymph node concept in prostate cancer - first results of gamma probe-guided sentinel lymph node identification. *Eur Urol* 1999;36:595-600.
- 99.** Varga J, Páczelt A, Tóth Z, et al. A prostata sentinel nyirokcsomója - a radikális prostatectomiát kísérő lymphadenectomia új szemlélete. *Magyar Urológia* 2001;13:145-50.
- 100.** Briganti A, Karakiewicz PI, Chun FK, et al. Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and external pelvic lymph node dissection. *Eur Urol* 2007;51:1573-81.
- 101.** Heidenreich A, Pfister D, Thuer D, et al. Percentage of positive biopsies predict lymph node involvement in men with low-risk prostate cancer undergoing radical prostatectomy and extend pelvic lymphadenectomy. *BJU Int* 2011;107:220-5.

SUPPLEMENTS

I.